- Home
- ACHC vs CGON Comparison
ACHC vs CGON Comparison
Compare ACHC & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- CGON
- Stock Information
- Founded
- ACHC 2005
- CGON 2010
- Country
- ACHC United States
- CGON United States
- Employees
- ACHC N/A
- CGON 113
- Industry
- ACHC Medical Specialities
- CGON
- Sector
- ACHC Health Care
- CGON
- Exchange
- ACHC Nasdaq
- CGON NYSE
- Market Cap
- ACHC 2.0B
- CGON 2.0B
- IPO Year
- ACHC N/A
- CGON 2024
- Fundamental
- Price
- ACHC $24.36
- CGON $26.51
- Analyst Decision
- ACHC Buy
- CGON Strong Buy
- Analyst Count
- ACHC 9
- CGON 10
- Target Price
- ACHC $47.94
- CGON $64.44
- AVG Volume (30 Days)
- ACHC 1.9M
- CGON 793.0K
- Earning Date
- ACHC 07-30-2025
- CGON 08-07-2025
- Dividend Yield
- ACHC N/A
- CGON N/A
- EPS Growth
- ACHC N/A
- CGON N/A
- EPS
- ACHC 2.04
- CGON N/A
- Revenue
- ACHC $3,156,417,000.00
- CGON $662,000.00
- Revenue This Year
- ACHC $7.83
- CGON N/A
- Revenue Next Year
- ACHC $8.56
- CGON $25,206.93
- P/E Ratio
- ACHC $11.94
- CGON N/A
- Revenue Growth
- ACHC 5.48
- CGON 224.51
- 52 Week Low
- ACHC $20.36
- CGON $14.80
- 52 Week High
- ACHC $82.41
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- ACHC 60.32
- CGON 54.72
- Support Level
- ACHC $22.94
- CGON $25.80
- Resistance Level
- ACHC $25.04
- CGON $27.56
- Average True Range (ATR)
- ACHC 0.97
- CGON 1.00
- MACD
- ACHC 0.37
- CGON 0.04
- Stochastic Oscillator
- ACHC 85.47
- CGON 67.97
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.